


Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution
A new, cheaper naloxone is coming to pharmacy shelves, funded in part by Purdue Pharma’s bankruptcy

FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE

Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray
